HealthCare Global Enterprises Ltd

📢 HCG Proposes Key Shareholder Approvals: ESOS 2026, Leadership Remuneration & Director Reappointment

- Proposed HCG ESOS 2026: Up to 74,21,455 stock options (4.97% of equity) for employees.

- CEO Dr. Manish Mattoo to get 18,55,364 options (1.24% equity).

- Reappointment of Independent Director Mr. Rajiv Maliwal for 5 years at ₹35 Lakh/year.

- CEO remuneration revision: ₹2.75cr base pay + ₹1.25cr variable (up to 120% performance-linked).

- E-voting period: June 09-July 08, 2026; results by July 10, 2026.

- Exercise price of Options: ₹495/share before June 30, 2026; post-deadline price ≥₹495.

- Maximum vesting period: 7 years; exercise window: 10 years from grant.

- Physical shareholders must update PAN, address & bank details for compliance.